Latest On PURE Bioscience, Inc (PURE):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-03-20 08:44 EST | News | PURE Bioscience GAAP EPS of -$0.01, revenue of $0.4M | N/A |  |
| 2022-12-15 04:58 EST | News | PURE Bioscience GAAP EPS of -$0.01, revenue of $0.47M | N/A | |
| 2022-10-29 02:30 EST | News | PURE Bioscience GAAP EPS of -$0.04, revenue of $1.81M | N/A | |
| 2022-06-15 04:23 EST | News | PURE Bioscience GAAP EPS of -$0.01, revenue of $0.5M | N/A | |
| 2022-03-16 23:52 EST | News | PURE Bioscience GAAP EPS of -$0.01, revenue of $0.42M | N/A | |
| 2021-07-22 17:46 EST | News | PURE Bioscience reports FQ3 results | N/A | |
| 2021-03-18 07:55 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-17 17:23 EST | News | PURE Bioscience reports FQ2 results | N/A | |
| 2020-12-17 07:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-16 01:00 EST | News | PURE Bioscience reports FQ1 results | N/A | |
| 2020-12-04 06:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-27 01:07 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-12 03:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-10 12:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-09 20:30 EST | News | PURE Bioscience reports FY results | N/A | |
| 2020-10-08 21:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-04 15:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 16:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 09:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 12:56 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 16:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-04 19:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 12:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 04:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 20:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 08:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 01:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 15:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 16:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 21:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 12:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 07:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-03 07:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-02 23:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-02 07:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 20:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 04:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-29 23:25 EST | Analyst Rating | The Analyst Target Price has increased from $0 to $5.25. | Buy | |
| 2020-06-29 23:25 EST | Stock Split | A stock split has occured on Aug 15, 2012 with a split factor of 1:8. | Neutral | |
| 2020-06-25 03:45 EST | News | Pure Bioscience inks deal for use of disinfectant in the transportation industry | N/A | |
| 2020-06-25 03:43 EST | News | PURE Bioscience reports Q3 results | N/A | |
| 2020-06-23 11:31 EST | Insider Trade | Tom Y Lee has acquired 1,000,000 shares indirectly via Plum Investments, L.P.. | Buy | |
| 2020-06-23 11:31 EST | Insider Trade | Dale Okuno has directly acquired 862,068 shares and currently holds 6,309,420 shares. | Buy | |
| 2020-06-23 11:31 EST | Insider Trade | Tom Y Lee has acquired 754,884 shares indirectly via Plum Investments, L.P.. | Buy | |
| 2020-06-23 11:31 EST | Insider Trade | Dale Okuno has directly disposed of 40,000 shares and currently holds 5,520,540 shares. | Sell | |
| 2020-06-23 11:31 EST | Insider Trade | Dale Okuno has directly disposed of 748,880 shares and currently holds 5,560,540 shares. | Sell | |
| 2020-06-23 11:31 EST | Insider Trade | Ivan Chen has directly acquired 179,311 shares and currently holds 450,000 shares. | Buy | |
| 2020-06-23 11:31 EST | Insider Trade | Tom Y Lee has acquired 2,243,103 shares indirectly via Plum Investments, L.P.. | Buy | |
| 2020-06-23 11:31 EST | Insider Trade | Dale Okuno has directly acquired 1,551,724 shares and currently holds 7,072,264 shares. | Buy | |
| 2020-06-23 11:31 EST | Insider Trade | Tom Y Lee has directly acquired 26,876 shares and currently holds 4,564,523 shares. | Buy | |
About PURE Bioscience, Inc (PURE):
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. It manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection and formulates with other compounds. The company offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. It also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. The company was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.
General
- Name PURE Bioscience, Inc
- Symbol PURE
- Type Common Stock
- Exchange OTCQB
- Currency USD
- Country USA
- SectorConsumer Defensive
- IndustryHousehold & Personal Products
- Full Time Employees 10
- Last Split Factor1:8
- Last Split Date2012-08-15
- Fiscal Year EndJuly
- IPO Date1996-08-08
- Gic SectorConsumer Staples
- Gic GroupHousehold & Personal Products
- Gic IndustryHousehold Products
- Gic SubIndustryHousehold Products
- Web URLhttp://www.purebio.com
View More
Valuation
- Trailing PE 97.5
- Price/Sales (Trailing 12 Mt.) 7.94
- Price/Book (Most Recent Quarter) 13.28
- Enterprise Value Revenue 7.53
- Enterprise Value EBITDA 53.65
View More
Financials
- Most Recent Quarter 2021-01-31
- Profit Margin 12%
- Operating Margin 12%
- Return on Assets 19%
- Return on Equity 39%
- Revenue 8.68 million
- Earnings Per Share $0.01
- Revenue Per Share $0.1
- Gross Profit 4.02 million
- Quarterly Earnings Growth 162.5%
View More
Highlights
- Market Capitalization 68.03 million
- EBITDA 1.21 million
- PE Ratio -2.18
- Analyst Target Price $5.25
- Book Value Per Share $0.05
View More
Share Statistics
- Shares Outstanding 87.22 million
- Shares Float 57.64 million
- % Held by Insiders 3432%
- % Held by Institutions 0.03%
- Shares Short 222969
- Shares Short Prior Month 254799
- Short Ratio 2.56
- Short % of Float 2%
- Short % of Shares Outstanding 2%
View More
Technicals
- Beta 0.09
- 52 Week High $2.01
- 52 Week Low $0.54
- 50 Day Moving Average 0.76
- 200 Day Moving Average 1.09
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
PURE Bioscience, Inc (PURE) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
PURE Bioscience, Inc (PURE) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2021-01-31 | 2021-03-16 | $N/A | -$0.01 | ||
| 2020-10-31 | 2020-12-15 | $1.59 million | $-0.00 | ||
| 2020-07-31 | 2020-10-31 | $N/A | $-0.00 | ||
| 2020-04-30 | 2020-07-31 | $2.22 million | $0.02 | ||
| 2020-01-31 | 2020-04-30 | $349000 | $0.01 | ||
| 2019-10-31 | 2020-01-31 | $398000 | -$0.01 | ||
| 2019-07-31 | 2019-10-31 | $613000 | -$0.01 | ||
| 2019-04-30 | 2019-07-31 | $312000 | -$0.01 | ||
| 2019-01-31 | 2019-04-30 | $394000 | -$0.03 | ||
| 2018-10-31 | 2019-01-31 | $590000 | -$0.02 | ||
| 2018-07-31 | 2018-10-31 | $509000 | -$0.04 | ||
| 2018-04-30 | 2018-07-31 | $390000 | -$0.02 | -$0.02 | -1.5% |
| 2018-01-31 | 2018-03-14 | $411000 | -$0.03 | -$0.02 | -50% |
| 2017-10-31 | 2017-12-14 | $464000 | -$0.04 | -$0.02 | -100% |
| 2017-07-31 | 2017-10-26 | $515000 | -$0.02 | -$0.03 | 23.33% |
| 2017-04-30 | 2017-06-08 | $338000 | -$0.02 | -$0.02 | -5% |
| 2017-01-31 | 2017-03-02 | $447000 | -$0.02 | -$0.02 | -10% |
| 2016-10-31 | 2016-12-14 | $531000 | -$0.03 | ||
| 2016-07-31 | 2016-10-27 | $524000 | -$0.02 | -$0.03 | 30% |
| 2016-04-30 | 2016-06-09 | $403000 | -$0.02 | -$0.03 | 33.33% |
| 2016-01-31 | 2016-03-09 | $176000 | -$0.03 | -$0.03 | 15.33% |
| 2015-10-31 | 2015-12-10 | $186000 | -$0.07 | ||
| 2015-07-31 | 2015-10-28 | $230000 | -$0.04 | ||
| 2015-04-30 | 2015-06-11 | $109000 | -$0.05 | ||
| 2015-01-31 | 2015-03-04 | $273000 | -$0.04 | ||
| 2014-10-31 | 2014-12-11 | $117000 | -$0.05 | ||
| 2014-07-31 | 2014-10-28 | $133000 | -$0.09 | ||
| 2014-04-30 | 2014-06-10 | $261000 | -$0.07 | ||
| 2014-01-31 | 2014-03-13 | $41000 | -$0.10 | ||
| 2013-10-31 | 2013-12-13 | $115000 | -$0.19 | ||
| 2013-07-31 | 2013-10-25 | $189000 | -$0.20 | ||
| 2013-04-30 | 2013-06-14 | $258000 | -$0.14 | ||
| 2013-01-31 | 2013-02-26 | $263000 | -$0.17 | ||
| 2012-10-31 | 2012-12-12 | $110000 | -$0.25 | ||
| 2012-07-31 | 2012-10-03 | $127000 | -$0.45 | ||
| 2012-04-30 | 2012-06-14 | $207000 | -$0.31 | ||
| 2012-01-31 | 2012-03-19 | $221000 | -$0.41 | ||
| 2011-10-31 | 2011-12-15 | $257000 | -$0.48 | -$0.24 | -100% |
| 2011-07-31 | 2011-10-31 | $244000 | -$0.40 | -$0.32 | -25% |
| 2011-04-30 | 2011-06-13 | $129000 | -$0.40 | -$0.48 | 16.67% |
| 2011-01-31 | 2011-03-18 | $68000 | -$0.54 | ||
| 2010-10-31 | 2010-12-16 | $23000 | -$0.45 | ||
| 2010-07-31 | 2010-10-29 | $324000 | -$0.39 | ||
| 2010-04-30 | 2010-06-10 | $563000 | -$0.37 | ||
| 2010-01-31 | 2010-03-12 | $327000 | -$0.41 | ||
| 2009-10-31 | 2009-12-11 | $222000 | -$0.41 | ||
| 2009-07-31 | 2009-10-14 | $202000 | -$32.16 | ||
| 2009-04-30 | 2009-06-10 | $130000 | -$0.40 | ||
| 2009-01-31 | 2009-03-13 | $285000 | -$0.59 | ||
| 2008-10-31 | 2008-12-11 | $111000 | -$0.43 | ||
| 2008-07-31 | 2008-10-15 | $823000 | -$0.44 | ||
| 2008-04-30 | 2008-06-13 | $416000 | -$0.70 | ||
| 2008-01-31 | 2008-03-17 | $153000 | -$0.48 | -$0.40 | -20% |
| 2007-10-31 | 2007-12-17 | $95000 | -$0.32 | -$0.40 | 20% |
| 2007-07-31 | 2007-10-29 | $7000 | -$0.64 | -$0.32 | -100% |
| 2007-04-30 | 2007-06-15 | $133000 | -$0.24 | -$0.32 | 25% |
| 2007-01-31 | 2007-03-20 | $168000 | -$0.24 | -$0.32 | 25% |
| 2006-10-31 | 2006-12-18 | $28000 | -$0.40 | -$0.32 | -25% |
| 2006-07-31 | 2006-10-30 | $41000 | -$0.32 | -$0.32 | 0% |
| 2006-04-30 | 2006-06-15 | $44000 | -$0.32 | -$0.32 | 0% |
| 2006-01-31 | 2006-03-17 | $60000 | -$0.40 | $0.08 | -600% |
| 2005-10-31 | 2005-12-16 | $55000 | -$0.32 | ||
| 2005-04-30 | 2005-06-15 | $42000 | -$0.32 | -$0.32 | 0% |
| 2005-01-31 | 2005-03-18 | $51000 | -$0.24 | ||
| 2004-10-31 | 2004-12-16 | $25000 | -$0.24 | ||
| 2004-01-31 | 2004-03-16 | $55000 | -$0.40 | ||
| 2003-07-31 | 2003-10-29 | $36000 | -$0.72 | ||
| 2002-10-31 | 2002-10-31 | $36000 | -$0.44 | ||
| 2001-10-31 | 2001-10-31 | $864000 | -$0.35 | ||
| 2000-10-31 | 2000-10-31 | $366000 | -$0.38 | ||
| 1999-10-31 | 1999-10-31 | $0.15 | |||
| 1999-01-31 | 1999-01-31 | $0.17 | |||
| 1998-10-31 | 1998-10-31 | $0.15 |
PURE Bioscience, Inc (PURE) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Jan 31 2021 | Oct 31 2020 | Jul 31 2020 | Apr 30 2020 | Jan 31 2020 |
|---|---|---|---|---|---|
| Research Development | N/A | 83000 | N/A | 85000 | 60000 |
| Income Before Tax | N/A | -180000 | N/A | 473000 | -666000 |
| Selling General Administrative | N/A | 1.05 million | N/A | 690000 | 810000 |
| Gross Profit | N/A | 950000 | N/A | 1.25 million | 207000 |
| Ebit | N/A | -134000 | N/A | 519000 | -617000 |
| Operating Income | N/A | -179000 | N/A | 474000 | -663000 |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | 1.59 million | N/A | 2.22 million | 349000 |
| Cost of Revenue | N/A | 641000 | N/A | 972000 | 142000 |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -2000 |
| Net Income From Continuing Operations | N/A | -180000 | N/A | 473000 | -666000 |
| Net Income Applicable to Common Shares | -595000 | N/A | 1.32 million | 473000 | -666000 |
Cash Flow:
| Date | Oct 31 2020 | Jul 31 2020 | Apr 30 2020 | Jan 31 2020 | Oct 31 2019 |
|---|---|---|---|---|---|
| Investments | -174000 | N/A | N/A | -44000 | N/A |
| Change to Liabilities | N/A | 21000 | 799000 | -185000 | 139000 |
| Total Cash Flow from Investing Activities | N/A | -14000 | N/A | -44000 | -44000 |
| Net Borrowings | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | N/A | N/A | 2 million | N/A | 830000 |
| Change to Operating Activities | N/A | -5000 | 5000 | 15000 | -20000 |
| Change in Cash | -373000 | N/A | 1.78 million | -658000 | 506000 |
| Total Cash from Operating Activities | -199000 | 1.83 million | -224000 | -614000 | -324000 |
| Depreciation | 45000 | N/A | 45000 | 48000 | 52000 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | -186000 | N/A | -141000 | 21000 | 15000 |
| Change to Account Receivables | 529000 | N/A | -1.45 million | 64000 | 153000 |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | N/A | 194000 | 46000 | 89000 | 462000 |
| Capital Expenditures | 174000 | N/A | N/A | 44000 | 44000 |
Balance Sheet:
| Date | Jan 31 2021 | Oct 31 2020 | Jul 31 2020 | Apr 30 2020 | Jan 31 2020 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | 906000 | N/A | 1.49 million | 692000 |
| Total Stockholder Equity | N/A | 4.86 million | N/A | 3.3 million | 776000 |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Assets | N/A | 5.77 million | N/A | 4.79 million | 1.47 million |
| Common Stock | 873000 | N/A | 871000 | 869000 | 800000 |
| Other Current Assets | 75000 | N/A | 75000 | N/A | 75000 |
| Retained Earnings | -124.25 million | -123.65 million | -123.47 million | -124.8 million | -125.27 million |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A |
| Cash | N/A | 3.47 million | N/A | 2.02 million | 246000 |
| Total Current Liabilities | 780000 | 906000 | 1.51 million | 1.49 million | 692000 |
| Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Property, Plant & Equipment | 771000 | N/A | 316000 | 328000 | 351000 |
| Total Current Assets | 4.12 million | 4.88 million | 5.57 million | 4 million | 633000 |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 4.11 million | N/A | 4.37 million | 2.83 million | 292000 |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | 618000 | 733000 | 547000 | 282000 | 141000 |
| Accounts Payable | 617000 | 773000 | 1.34 million | 1.29 million | 589000 |
PURE Bioscience, Inc (PURE) Chart:
PURE Bioscience, Inc (PURE) News:
Below you will find a list of latest news for PURE Bioscience, Inc (PURE) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
PURE Bioscience, Inc (PURE) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
PURE Bioscience, Inc (PURE) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1006028/000120919120039138/0001209191-20-039138-index.htm |
| 2019-08-06 | 5 | Annual statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1006028/000120919119044879/0001209191-19-044879-index.htm |
| 2019-10-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1006028/000120919119052409/0001209191-19-052409-index.htm |
| 2019-10-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1006028/000120919119052410/0001209191-19-052410-index.htm |
| 2019-10-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1006028/000120919119052412/0001209191-19-052412-index.htm |
| 2020-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1006028/000120919120005909/0001209191-20-005909-index.htm |
| 2020-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1006028/000120919120005910/0001209191-20-005910-index.htm |
| 2020-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1006028/000120919120005911/0001209191-20-005911-index.htm |
| 2020-02-06 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1006028/000120919120007271/0001209191-20-007271-index.htm |
| 2020-02-06 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1006028/000120919120007273/0001209191-20-007273-index.htm |
| 2020-02-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1006028/000120919120008081/0001209191-20-008081-index.htm |
| 2020-02-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1006028/000120919120008082/0001209191-20-008082-index.htm |
| 2020-03-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1006028/000120919120018605/0001209191-20-018605-index.htm |
| 2020-03-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1006028/000120919120018612/0001209191-20-018612-index.htm |
| 2020-03-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1006028/000120919120018614/0001209191-20-018614-index.htm |
| 2020-05-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1006028/000120919120030646/0001209191-20-030646-index.htm |
| 2020-05-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1006028/000120919120030695/0001209191-20-030695-index.htm |
| 2020-05-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1006028/000120919120030696/0001209191-20-030696-index.htm |
| 2020-05-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1006028/000120919120030699/0001209191-20-030699-index.htm |
| 2020-05-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1006028/000120919120030704/0001209191-20-030704-index.htm |
| 2020-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1006028/000120919120037706/0001209191-20-037706-index.htm |
| 2020-06-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1006028/000120919120038300/0001209191-20-038300-index.htm |
| 2020-06-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1006028/000120919120038334/0001209191-20-038334-index.htm |
| 2020-06-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1006028/000120919120039138/0001209191-20-039138-index.htm |
| 2019-10-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1006028/000149315219014962/0001493152-19-014962-index.htm |
| 2019-10-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1006028/000149315219016111/0001493152-19-016111-index.htm |
| 2019-10-30 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1006028/000149315219016126/0001493152-19-016126-index.htm |
| 2019-10-31 | POS AM | Post-Effective amendments for registration statement | https://www.sec.gov/Archives/edgar/data/1006028/000149315219016297/0001493152-19-016297-index.htm |
| 2019-11-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1006028/000149315219018122/0001493152-19-018122-index.htm |
| 2019-12-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1006028/000149315219019179/0001493152-19-019179-index.htm |
| 2019-12-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1006028/000149315219019180/0001493152-19-019180-index.htm |
| 2019-12-17 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1006028/000149315219019354/0001493152-19-019354-index.htm |
| 2019-12-20 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1006028/000149315219019488/0001493152-19-019488-index.htm |
| 2020-02-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1006028/000149315220001579/0001493152-20-001579-index.htm |
| 2020-03-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1006028/000149315220003814/0001493152-20-003814-index.htm |
| 2020-03-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1006028/000149315220003816/0001493152-20-003816-index.htm |
| 2020-03-13 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1006028/000149315220003896/0001493152-20-003896-index.htm |
| 2020-05-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1006028/000149315220009591/0001493152-20-009591-index.htm |
| 2020-06-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1006028/000149315220011000/0001493152-20-011000-index.htm |
| 2020-06-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1006028/000149315220011005/0001493152-20-011005-index.htm |
| 2020-06-15 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1006028/000149315220011181/0001493152-20-011181-index.htm |
| 2020-10-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1006028/000149315220019152/0001493152-20-019152-index.htm |
| 2020-10-08 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1006028/000149315220019153/0001493152-20-019153-index.htm |
| 2020-10-20 | POS AM | Post-Effective amendments for registration statement | https://www.sec.gov/Archives/edgar/data/1006028/000149315220019633/0001493152-20-019633-index.htm |
| 2019-11-04 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1006028/999999999519002464/9999999995-19-002464-index.htm |
| 2020-10-23 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1006028/999999999520002959/9999999995-20-002959-index.htm |
PURE Bioscience, Inc (PURE) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of PURE Bioscience, Inc (PURE). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 3432%Institutional Ownership: 3%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2019-10-02 | Tom Y Lee | Director | Buy | 1,000,000.00 | 0.29 | 290,000.00 | 22,136,186.00 | https://www.sec.gov/Archives/edgar/data/1006028/000120919119052410/0001209191-19-052410-index.htm |
| 2019-12-19 | Tom Y Lee | Director | Buy | 754,884.00 | 0.29 | 218,161.48 | 22,891,070.00 | https://www.sec.gov/Archives/edgar/data/1006028/000120919120008081/0001209191-20-008081-index.htm |
| 2020-03-09 | Tom Y Lee | Director | Buy | 2,243,103.00 | 0.29 | 650,499.87 | 24,134,173.00 | https://www.sec.gov/Archives/edgar/data/1006028/000120919120018612/0001209191-20-018612-index.htm |
| 2020-06-12 | Tom Y Lee | Chief Executive Officer | Buy | 45,157.00 | 1.91 | 86,204.71 | 4,407,647.00 | https://www.sec.gov/Archives/edgar/data/1006028/000120919120037706/0001209191-20-037706-index.htm |
| 2020-06-15 | Tom Y Lee | Chief Executive Officer | Buy | 60,000.00 | 1.82 | 109,200.00 | 4,467,647.00 | https://www.sec.gov/Archives/edgar/data/1006028/000120919120037706/0001209191-20-037706-index.htm |
| 2020-03-09 | Ivan Chen | Director | Buy | 179,311.00 | 0.29 | 52,000.19 | 450,000.00 | https://www.sec.gov/Archives/edgar/data/1006028/000120919120018605/0001209191-20-018605-index.htm |
| 2020-06-16 | Tom Y Lee | Chief Executive Officer | Buy | 70,000.00 | 1.62 | 113,330.00 | 4,537,647.00 | https://www.sec.gov/Archives/edgar/data/1006028/000120919120037706/0001209191-20-037706-index.htm |
| 2020-06-17 | Tom Y Lee | Chief Executive Officer | Buy | 26,876.00 | 1.61 | 43,135.98 | 4,564,523.00 | https://www.sec.gov/Archives/edgar/data/1006028/000120919120037706/0001209191-20-037706-index.htm |
| 2020-06-18 | Tom Y Lee | Chief Executive Officer | Buy | 30,000.00 | 1.75 | 52,497.00 | 4,594,523.00 | https://www.sec.gov/Archives/edgar/data/1006028/000120919120038334/0001209191-20-038334-index.htm |
| 2020-06-19 | Tom Y Lee | Chief Executive Officer | Buy | 10,000.00 | 1.85 | 18,500.00 | 4,604,523.00 | https://www.sec.gov/Archives/edgar/data/1006028/000120919120038334/0001209191-20-038334-index.htm |
| 2020-06-22 | Tom Y Lee | Chief Executive Officer | Buy | 13,124.00 | 1.72 | 22,573.28 | 4,617,647.00 | https://www.sec.gov/Archives/edgar/data/1006028/000120919120038334/0001209191-20-038334-index.htm |
| 2019-12-31 | Dale Okuno | Director | Sell | 40,000.00 | 0.28 | 11,200.00 | 5,520,540.00 | https://www.sec.gov/Archives/edgar/data/1006028/000120919120008082/0001209191-20-008082-index.htm |
| 2020-05-01 | Thomas Richard Myers | Chief Operating Officer | Buy | 500,000.00 | 587,500.00 | https://www.sec.gov/Archives/edgar/data/1006028/000120919120038300/0001209191-20-038300-index.htm | ||
| 2019-10-02 | Dale Okuno | Director | Buy | 862,068.00 | 0.29 | 249,999.72 | 6,309,420.00 | https://www.sec.gov/Archives/edgar/data/1006028/000120919119052412/0001209191-19-052412-index.htm |
| 2020-03-09 | Dale Okuno | Director | Buy | 1,551,724.00 | 0.29 | 449,999.96 | 7,072,264.00 | https://www.sec.gov/Archives/edgar/data/1006028/000120919120018614/0001209191-20-018614-index.htm |